Paradigm Biopharmaceuticals (ASX:PAR) - Cotización, noticias y análisis

Resumen de acción PAR

Paradigm Biopharmaceuticals Limited se dedica a la investigación y desarrollo de productos terapéuticos para uso humano en Australia.

Acerca de la empresa

PAR fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Recompensas

Cotiza un 98% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 105.3%

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares (A$42K)

Tiene menos de 1 año de cash runway

Los accionistas han sido diluidos en el último año

No tiene una capitalización de mercado significativa (A$100M)

Competidores de Paradigm Biopharmaceuticals Limited

Race Oncology

ASX:RAC

AU$202.7m

Orthocell

ASX:OCC

AU$82.7m

BCAL Diagnostics

ASX:BDX

AU$23.5m

Actinogen Medical

ASX:ACW

AU$74.5m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Paradigm Biopharmaceuticals
Historical stock prices
Current Share Price	AU$0.24
52 Week High	AU$1.09
52 Week Low	AU$0.24
Beta	0.96
1 Month Change	-28.99%
3 Month Change	-27.94%
1 Year Change	-76.89%
3 Year Change	-89.11%
5 Year Change	-83.10%
Change since IPO	-33.78%

Noticias y actualizaciones recientes

Recent updates

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Aug 22

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Apr 17

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Sep 21

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Jun 20

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Dec 02

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Jun 07

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Feb 22

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Jan 24

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Dec 28

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Nov 29

Rentabilidad de los accionistas

	PAR	AU Biotechs	Mercado AU
7D	-9.3%	1.1%	0.7%
1Y	-76.9%	-7.4%	6.3%

Rentabilidad vs. Industria: PAR obtuvo unos resultados inferiores a los del sector Australian Biotechs , que el año pasado arrojó un rendimiento del -8.1%.

Rentabilidad vs. Mercado: PAR obtuvo unos resultados inferiores a los del mercado Australian, que fue del 3.9% el año pasado.

Volatilidad de los precios

Is PAR's price volatile compared to industry and market?
PAR volatility
PAR Average Weekly Movement	10.2%
Biotechs Industry Average Movement	11.2%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.5%

Precio estable de las acciones: El precio de las acciones de PAR ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de PAR (12%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2014	n/a	Paul Rennie	www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Limited se dedica a la investigación y desarrollo de productos terapéuticos para uso humano en Australia. Ofrece medicamentos de pentosano polisulfato sódico en forma inyectable para el tratamiento de la artrosis, la mucopolisacaridosis, el virus del río Ross, el virus chikungunya, la insuficiencia cardiaca crónica, las enfermedades respiratorias alérgicas y el síndrome de dificultad respiratoria aguda. La empresa se constituyó en 2014 y tiene su sede en Melbourne (Australia).

Resumen de fundamentos de Paradigm Biopharmaceuticals Limited

¿Cómo se comparan los beneficios e ingresos de Paradigm Biopharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de PAR
Capitalización bursátil	AU$85.84m
Beneficios(TTM)	-AU$69.00m
Ingresos (TTM)	AU$42.05k

2,041x

Ratio precio-ventas (PS)

-1.2x

Ratio precio-beneficio (PE)

¿Está PAR sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de PAR
Ingresos	AU$42.05k
Coste de los ingresos	AU$11.47k
Beneficio bruto	AU$30.58k
Otros gastos	AU$69.03m
Beneficios	-AU$69.00m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.20
Margen bruto	72.73%
Margen de beneficio neto	-164,092.68%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado PAR a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción PAR

Recompensas

Análisis de riesgos

Competidores de Paradigm Biopharmaceuticals Limited

ASX:RAC

AU$202.7m

ASX:OCC

AU$82.7m

ASX:BDX

AU$23.5m

ASX:ACW

AU$74.5m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Insufficient new directors

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Market cap size

New minor risk - Share price stability

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Recent updates

Insufficient new directors

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Market cap size

New minor risk - Share price stability

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Consensus EPS estimates fall from profit to AU$0.18 loss

Forecast breakeven date pushed back to 2025

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Founder recently bought AU$76k worth of stock

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee (DMC) for the Pivotal Para_OA_002 Clinical Trial

Founder recently bought AU$62k worth of stock

Paradigm Biopharmaceuticals Limited Announces Executive Changes

Price target increased to AU$2.20

Paradigm Biopharmaceuticals Limited Announces an Abstract on Paradigm's Phase 2 Clinical Trial Evaluating Injectable Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Announces First UK Subject Randomised and Dosed for the Pivotal Phase 3 Trial for the Treatment of Pain Associated with Knee OA

Paradigm Biopharmaceuticals Ltd Announces Successful Primary Endpoint in Phase 2 Trial

Paradigm Biopharmaceuticals Ltd Provides an Update on the Ongoing Multi-Centre Double-Blind Randomised Phase 2 Study Comparing PPS to Placebo in Mucopolysaccharidosis Type VI (MPS-VI) Patients

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 18, 2022

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Appoints Abby Macnish as Interim Company Secretary

Paradigm Biopharmaceuticals Ltd Announces MPS Clinical Program Update and Paradigm to Present At the International Conference on Lysosomal Diseases

Paradigm Biopharmaceuticals Limited Reports Important Global Progress for the Para_Oa_002 Phase 3 Clinical Trial Evaluating Zilosul® for Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces PARA_OA_008 Study Evaluating Zilosul® Mechanism and Disease Modifying Effects Completes Recruitment

Forecast to breakeven in 2024

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Limited Announces Chief Executive Officer Changes

Paradigm Biopharmaceuticals Limited Doses First US Subjects Under Phase 3 Trial

Price target decreased to AU$2.64

U.S. Food and Drug Administration Grants Fast Track Designation for Paradigm Biopharmaceuticals Ltd of Phase 3 Program

Founder & Non-Executive Chairman recently bought AU$51k worth of stock

Price target increased to AU$4.49

Consensus forecasts updated

No longer forecast to breakeven

Paradigm Biopharmaceuticals Limited Announces First Subjects Randomised and Dosed in Para_0A_002 Phase 3 Study in Australia

Paradigm Biopharmaceuticals Ltd Reports Postive Topline Results in Heart Failure Model

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Reports Preliminary Results from Phase 2 Mps I Study

Paradigm Biopharmaceuticals Limited Announces First MPS-VI Patient Dosed Under Phase 2 Trial in Brazil Investigating PPS for the Treatment of MPS-VI

Paradigm Biopharmaceuticals Limited Receives Feedback from US FDA on IND Submission

Paradigm Biopharmaceuticals Limited Announces Australian Ethics Approval for Paradigm's ARA_OA_002 Pivotal Phase 3 Clinical Trial in Participants with Knee OA

Paradigm Biopharmaceuticals Limited Makes Progress with Investigational New Drug Application

Consensus EPS estimates increase to -AU$0.15

Paradigm Biopharmaceuticals Limited Receives Key Regulatory Approvals for MPS VI Study

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Ltd Receives First Revenue Through Physician Prescription of Zilosul to Patients Via the TGA SAS

Paradigm Biopharmaceuticals Ltd Provides an Update on its IND Application to the Us Food and Drug Administration

Paradigm Biopharmaceuticals Limited Updates Phase 2A, Randomised, Double-Blind, Placebo- Controlled Study

Analysts lower EPS estimates to -AU$0.17

New 90-day low: AU$2.28

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Paradigm Biopharmaceuticals Ltd Announces It Has Received Ethics Approval for Its Phase 2 Clinical Trial to Evaluate the Treatment Effects of Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Appoints Helen Fisher as Non-Executive Director and Chair of the Audit and Risk Committee

Paradigm Biopharmaceuticals Ltd Reports Ongoing Data Update on Patients Who Received Zilosul Under the Therapeutic Goods Administration (TGA) Special Access Scheme

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

New 90-day low: AU$2.38